Skip to main content

Accelerating Regenerative Medicine

Follow RegMed XB on LinkedIn
  • Upcoming events

    Banner DCVA RegMed XB Community Event

    DCVA & RegMed XB Community Event

    For academic researchers and healthcare innovators interested in valorization, entrepreneurship, and accelerating from lab to patient.

    read more
    Banner AC26

    RegMed XB Annual Conference 2026

    Be part of the 4th RegMed XB Annual Conference: Collaborate to Regenerate. Get inspired and expand your network within the regenerative medicine field.

    read more
  • Expertise

    Business Development & Valorization

    Accelerating Innovation in Regenerative Medicine

    read more

    Research Excellence: Moonshots

    Push the boundaries of research excellence

    read more

    Infrastructure: RegMed XB's Pilot Factory

    A seamless pathway for innovators to accelerate, de-risk, and scale regenerative therapies

    read more

    Public-Private Entrepreneurship

    Building ecosystems through collaboration

    read more

    Seed Capital

    Secure early-stage funding

    read more
  • Latest news

    News slider

    33 million euros from National Growth Fund for RegMed XB Pilot factory for regenerative medicine

    Promising therapies for patients one step closer. The urgency is high in the field of regenerative medicine. Promising therapies are in the pipeline from the lab to the patient, but a good infrastructure is needed to make this possible. 

    read more
    News slider

    A first step towards personalized prediction of thrombus formation risk and thromboembolism with regard to ex-vivo perfusion of organs such as the heart.

    Mohammad Rezaeimoghaddam and Frans van de Vosse have published a paper with the title ”Continuum modeling of thrombus formation and growth under different shear rates” in the Journal of Biomechanics.

    read more
    News slider

    FIRST participates in 1.8 million seed investment for the discovery of two new drugs for heart failure

    River BioMedics, a drug discovery company using advanced 3D human cardiac models, today announced the closure of a 1.8 million Euro seed funding round to progress its research and innovation programs for cardiovascular disease targets and compounds. River BioMedics addresses the high unmet medical need of cardiac diseases, with a focus on heart failure.

    read more
  • Moonshots (research excellence)

    Cardiovascular Moonshot

    Regeneration of the human heart

    read more

    Diabetes Moonshot

    A proof-of-concept therapy for Type 1 Diabetes

    read more

    Kidney Moonshot

    The first subunit of a bio-engineered kidney

    read more

    Osteoarthritis Moonshot

    The road to a bio-artificial joint

    read more
  • Pilot Factory (infrastructure)

    The RegMed XB Pilot Factory is one of the largest international infrastructures for regenerative medicine. It brings together all the expertise and infrastructure needed to bring regenerative medicine to the market.

    Pilot Factory

  • RegMed XB's Ecosystem

    Health Foundations

    The following Dutch health foundations are involved in defining research objectives and provide guidance in the research we conduct to ensure we maintain focus on the patient.

    read more

    Academic Partners

    RegMed XB works together with (inter)national top-rated academic institutions and collaborates specifically and exclusively with researchers who contribute specific expertise to the Moonshot initiatives.

    read more

    Industrial Partners

    Partnering with companies offers access to their expertise in designing scalable and feasible products. Currently, we have strong partnerships with the following entities.

    read more

    Governmental Partners

    RegMed XB receives support from national and local governments to de-risk promising concepts from academia to proof of concept or initial clinical trial stages.

    read more

    Life Science & Health partners

    The following Life Science & Health (LSH) partners are collaborate with RegMed XB.

    read more